Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Ditmarsch

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Future Cardiology|May 11, 2016
Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development programPeter Held, Anders Himmelmann, Marc Ditmarsch
Cardiovascular Research|December 1, 2021
Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?Nick S Nurmohamed, Marc Ditmarsch, John J P Kastelein
Alzheimer'S Research & Therapy|December 28, 2024
Correction: Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a mendelian randomization analysisAmand F Schmidt, Michael H Davidson, Marc Ditmarsch, et al.
American Heart Journal Plus : Cardiology Research and Practice|February 18, 2026
Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?Charles Shear, Michael H Davidson, Marc Ditmarsch, et al.
Alzheimer'S Research & Therapy|October 16, 2024
Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysisAmand F Schmidt, Michael H Davidson, Marc Ditmarsch, et al.
Current Atherosclerosis Reports|December 22, 2023
Obicetrapib: Reversing the Tide of CETP Inhibitor DisappointmentsJohn J P Kastelein, Andrew Hsieh, Mary R Dicklin, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2023
CETP and SGLT2 inhibitor combination therapy improves glycemic controlBohdan B Khomtchouk, Patrick Sun, Marc Ditmarsch, et al.
The American Journal of Cardiology|May 27, 2006
Effect of short-term rosuvastatin treatment on estimated glomerular filtration rateDonald G Vidt, Susan Harris, Fergus McTaggart, et al.
Frontiers in Endocrinology|July 4, 2024
CETP and SGLT2 inhibitor combination therapy increases glycemic control: a 2x2 factorial Mendelian randomization analysisBohdan B Khomtchouk, Patrick Sun, Zane A Maggio, et al.
Pharmacological Research|October 28, 2023
The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular diseaseNehal Mehta, Katerina Dangas, Marc Ditmarsch, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Future Cardiology|May 11, 2016
Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development programPeter Held, Anders Himmelmann, Marc Ditmarsch
Cardiovascular Research|December 1, 2021
Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?Nick S Nurmohamed, Marc Ditmarsch, John J P Kastelein
Alzheimer'S Research & Therapy|December 28, 2024
Correction: Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a mendelian randomization analysisAmand F Schmidt, Michael H Davidson, Marc Ditmarsch, et al.
American Heart Journal Plus : Cardiology Research and Practice|February 18, 2026
Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?Charles Shear, Michael H Davidson, Marc Ditmarsch, et al.
Alzheimer'S Research & Therapy|October 16, 2024
Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysisAmand F Schmidt, Michael H Davidson, Marc Ditmarsch, et al.
Current Atherosclerosis Reports|December 22, 2023
Obicetrapib: Reversing the Tide of CETP Inhibitor DisappointmentsJohn J P Kastelein, Andrew Hsieh, Mary R Dicklin, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2023
CETP and SGLT2 inhibitor combination therapy improves glycemic controlBohdan B Khomtchouk, Patrick Sun, Marc Ditmarsch, et al.
The American Journal of Cardiology|May 27, 2006
Effect of short-term rosuvastatin treatment on estimated glomerular filtration rateDonald G Vidt, Susan Harris, Fergus McTaggart, et al.
Frontiers in Endocrinology|July 4, 2024
CETP and SGLT2 inhibitor combination therapy increases glycemic control: a 2x2 factorial Mendelian randomization analysisBohdan B Khomtchouk, Patrick Sun, Zane A Maggio, et al.
Pharmacological Research|October 28, 2023
The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular diseaseNehal Mehta, Katerina Dangas, Marc Ditmarsch, et al.
Pageof 4